{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:37:09Z","timestamp":1791988629364,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T00:00:00Z","timestamp":1560902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","award":["Else Kr\u00f6ner-Forschungskolleg: Cancer Immunotherapy"],"award-info":[{"award-number":["Else Kr\u00f6ner-Forschungskolleg: Cancer Immunotherapy"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1266-0","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T11:02:39Z","timestamp":1560942159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":492,"title":["Advances in cancer immunotherapy 2019 \u2013 latest trends"],"prefix":"10.1186","volume":"38","author":[{"given":"Stephan","family":"Kruger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno L.","family":"Cadilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesa","family":"Schuebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard W.","family":"Renz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G.","family":"D\u2019Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Schloesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"issue":"3","key":"1266_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/imm.13008","volume":"155","author":"DM Altmann","year":"2018","unstructured":"Altmann DM. A Nobel prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology. 2018;155(3):283\u20134.","journal-title":"Immunology."},{"issue":"10","key":"1266_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"1","key":"1266_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"1266_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/annonc\/mdx755","volume":"29","author":"J Tang","year":"2018","unstructured":"Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84\u201391.","journal-title":"Ann Oncol"},{"issue":"9","key":"1266_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"1266_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc.6605465","volume":"102","author":"WM Liu","year":"2010","unstructured":"Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer. 2010;102(1):115\u201323.","journal-title":"Br J Cancer"},{"issue":"11","key":"1266_CR7","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","volume":"20","author":"SV Hato","year":"2014","unstructured":"Hato SV, Khong A, de Vries IJ, Lesterhuis WJ. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014;20(11):2831\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1266_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690\u2013714.","journal-title":"Cancer Cell"},{"issue":"4","key":"1266_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482\u201391.","journal-title":"Oncogene."},{"issue":"7550","key":"1266_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature14395","volume":"521","author":"S Shalapour","year":"2015","unstructured":"Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94\u20138.","journal-title":"Nature."},{"issue":"8","key":"1266_CR11","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052\u201361.","journal-title":"Cancer Res"},{"key":"1266_CR12","doi-asserted-by":"crossref","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1810865"},{"issue":"22","key":"1266_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"1266_CR14","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"Peter Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"New England Journal of Medicine"},{"issue":"suppl_8","key":"1266_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.045","volume":"29","author":"B Burtness","year":"2018","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, De Castro JG, et al. LBA8_PRKEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC). Ann Oncol. 2018;29(suppl_8):mdy424.045-mdy424.045.","journal-title":"Ann Oncol"},{"issue":"2494","key":"1266_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1136\/bmj.2.2494.1146","volume":"2","author":"HD McCulloch","year":"1908","unstructured":"McCulloch HD. On the analogy between spontaneous recoveries from Cancer and the specific immunity induced by X ray irradiations of the lymphatic glands involved. Br Med J. 1908;2(2494):1146\u20138.","journal-title":"Br Med J"},{"issue":"305","key":"1266_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234\u201341.","journal-title":"Br J Radiol"},{"issue":"3","key":"1266_CR18","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1266_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12573","volume":"280","author":"N Brix","year":"2017","unstructured":"Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280(1):249\u201379.","journal-title":"Immunol Rev"},{"issue":"6","key":"1266_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced Abscopal effect. Cancer Immunol Res. 2015;3(6):610\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"1266_CR21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","volume":"25","author":"Linda Hammerich","year":"2019","unstructured":"Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S, et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019;25(5):814\u201324.","journal-title":"Nature Medicine"},{"issue":"15_suppl","key":"1266_CR22","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.1200\/JCO.2018.36.15_suppl.6009","volume":"36","author":"SM McBride","year":"2018","unstructured":"McBride SM, Sherman EJ, Tsai CJ, Baxi SS, Aghalar J, Eng J, et al. A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2018;36(15_suppl):6009.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1266_CR23","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in stage III non\u2013small-cell lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"key":"1266_CR24","doi-asserted-by":"crossref","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1809697"},{"issue":"suppl_8","key":"1266_CR25","doi-asserted-by":"publisher","first-page":"mdy291","DOI":"10.1093\/annonc\/mdy291","volume":"29","author":"C Faivre-Finn","year":"2018","unstructured":"Faivre-Finn C, Spigel DR, Senan S, Langer CJ, Raben D, Perez B, et al. 1363OEfficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol. 2018;29(suppl_8):mdy291\u2013mdy.","journal-title":"Ann Oncol"},{"issue":"9","key":"1266_CR26","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","volume":"5","author":"RK Shrimali","year":"2017","unstructured":"Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, et al. Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res. 2017;5(9):755\u201366.","journal-title":"Cancer Immunol Res."},{"issue":"7693","key":"1266_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538\u201343.","journal-title":"Nature."},{"issue":"6024","key":"1266_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (New York, NY). 2011;331(6024):1612\u20136.","journal-title":"Science (New York, NY)"},{"issue":"14","key":"1266_CR29","doi-asserted-by":"publisher","first-page":"18508","DOI":"10.18632\/oncotarget.7610","volume":"7","author":"NM Luheshi","year":"2016","unstructured":"Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. 2016;7(14):18508\u201320.","journal-title":"Oncotarget."},{"key":"1266_CR30","volume-title":"Annual Meeting of the American Association for Cancer Research; Atlanta","author":"MH O'Hara","year":"2019","unstructured":"O'Hara MH. CT004 - a phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. In: Annual Meeting of the American Association for Cancer Research; Atlanta; 2019."},{"issue":"7652","key":"1266_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60\u20135.","journal-title":"Nature."},{"issue":"20","key":"1266_CR32","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clin Cancer Res. 2018;24(20):4960\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1266_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, et al. Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer. 2018;6(1):83.","journal-title":"J Immunother Cancer."},{"issue":"5","key":"1266_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522\u201330.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1266_CR35","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AM Eggermont","year":"2016","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845\u201355.","journal-title":"N Engl J Med"},{"issue":"19","key":"1266_CR36","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med"},{"issue":"12","key":"1266_CR37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MC, Harjunpaa H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery. 2016;6(12):1382\u201399.","journal-title":"Cancer Discovery"},{"key":"1266_CR38","doi-asserted-by":"crossref","unstructured":"Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018.","DOI":"10.1038\/s41591-018-0198-0"},{"issue":"21","key":"1266_CR39","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in Resectable lung Cancer. N Engl J Med. 2018;378(21):1976\u201386.","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"1266_CR40","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1200\/JCO.2018.36.15_suppl.6011","volume":"36","author":"RB Bell","year":"2018","unstructured":"Bell RB, Duhen R, Leidner RS, Curti BD, Ballesteros-Merino C, Piening B, et al. Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma. J Clin Oncol. 2018;36(15_suppl):6011.","journal-title":"J Clin Oncol"},{"issue":"suppl_8","key":"1266_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.047","volume":"29","author":"M Chalabi","year":"2018","unstructured":"Chalabi M, Fanchi LF, Van den Berg JG, Beets GL, Lopez-Yurda M, Aalbers AG, et al. LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29(suppl_8):mdy424.047-mdy424.047.","journal-title":"Ann Oncol"},{"issue":"302","key":"1266_CR42","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.","journal-title":"Sci Transl Med"},{"key":"1266_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415.","journal-title":"Nature."},{"issue":"15_suppl","key":"1266_CR44","doi-asserted-by":"publisher","first-page":"7014","DOI":"10.1200\/JCO.2018.36.15_suppl.7014","volume":"36","author":"TM Kadia","year":"2018","unstructured":"Kadia TM, Cortes JE, Ghorab A, Ravandi F, Jabbour E, Daver NG, et al. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. J Clin Oncol. 2018;36(15_suppl):7014.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1266_CR45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1158\/2159-8290.CD-ND2015-004","volume":"5","author":"J Colwell","year":"2015","unstructured":"Colwell J. Is PD-L1 expression a biomarker of response? Cancer discovery. 2015;5(12):1232.","journal-title":"Cancer discovery."},{"issue":"4","key":"1266_CR46","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","volume":"9","author":"DA Fabrizio","year":"2018","unstructured":"Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol. 2018;9(4):610\u20137.","journal-title":"J Gastrointest Oncol"},{"issue":"9","key":"1266_CR47","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.32002","volume":"144","author":"V Endris","year":"2019","unstructured":"Endris V, Buchhalter I, Allgauer M, Rempel E, Lier A, Volckmar AL, et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. Int J Cancer. 2019;144(9):2303\u201312.","journal-title":"Int J Cancer"},{"issue":"6230","key":"1266_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunologyMutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348(6230):124\u20138.","journal-title":"Science (New York, NY)"},{"issue":"1","key":"1266_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","volume":"30","author":"T A Chan","year":"2018","unstructured":"Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44\u201356.","journal-title":"Annals of Oncology"},{"issue":"suppl_8","key":"1266_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy303.005","volume":"29","author":"ME Salem","year":"2018","unstructured":"Salem ME, Puccini A, Grothey A, Xiu J, Goldberg R. Kim ES, et al. 1835PDComparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate\/low. Ann Oncol. 2018;29(suppl_8):mdy303.005-mdy303.005.","journal-title":"Ann Oncol"},{"issue":"25","key":"1266_CR51","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"22","key":"1266_CR52","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu T-E, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"6","key":"1266_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749\u201357.","journal-title":"Nat Med"},{"key":"1266_CR54","volume-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature medicine","author":"W Yang","year":"2019","unstructured":"Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nature medicine. 2019."},{"issue":"7","key":"1266_CR55","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","volume":"17","author":"X Frigola","year":"2011","unstructured":"Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17(7):1915\u201323.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1266_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1310358","volume":"6","author":"S Kruger","year":"2017","unstructured":"Kruger S, Legenstein ML, Rosgen V, Haas M, Modest DP, Westphalen CB, et al. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology. 2017;6(5):e1310358.","journal-title":"Oncoimmunology."},{"issue":"8","key":"1266_CR57","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1452581","volume":"7","author":"A Costantini","year":"2018","unstructured":"Costantini A, Julie C, Dumenil C, Helias-Rodzewicz Z, Tisserand J, Dumoulin J, et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018;7(8):e1452581.","journal-title":"Oncoimmunology."},{"issue":"9","key":"1266_CR58","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138.","journal-title":"Nat Med"},{"issue":"suppl_8","key":"1266_CR59","volume":"29","author":"ES Kim","year":"2018","unstructured":"Kim ES, Velcheti V, Mekhail T, Leal TA, Dowell JE, Tsai ML, et al. LBA55Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29(suppl_8):mdy424.067-mdy424.067.","journal-title":"Ann Oncol"},{"issue":"12","key":"1266_CR60","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","volume":"29","author":"S Kruger","year":"2018","unstructured":"Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29(12):2348\u201355.","journal-title":"Ann Oncol"},{"issue":"5","key":"1266_CR61","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","volume":"28","author":"JH Lee","year":"2017","unstructured":"Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28(5):1130\u20136.","journal-title":"Ann Oncol"},{"issue":"8","key":"1266_CR62","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1078-0432.CCR-17-1341","volume":"24","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early assessment of lung Cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872\u201380.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1266_CR63","doi-asserted-by":"publisher","first-page":"38056","DOI":"10.18632\/oncotarget.16935","volume":"8","author":"N Guibert","year":"2017","unstructured":"Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget. 2017;8(23):38056\u201360.","journal-title":"Oncotarget."},{"issue":"15_suppl","key":"1266_CR64","doi-asserted-by":"publisher","first-page":"9084","DOI":"10.1200\/JCO.2018.36.15_suppl.9084","volume":"36","author":"B Ricciuti","year":"2018","unstructured":"Ricciuti B, Giglio AD, Brambilla M, Bassanelli M, Metro G, Ludovini V, et al. Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: a multicenter analysis. J Clin Oncol. 2018;36(15_suppl):9084.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1266_CR65","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non\u2013small-cell lung cancer. JAMA Oncol. 2018;4(3):374\u20138.","journal-title":"JAMA Oncol"},{"issue":"suppl_8","key":"1266_CR66","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy288.014","volume":"29","author":"M Kfoury","year":"2018","unstructured":"Kfoury M, Voisin AL, Najean M, Champiat S, Laghouati S, Michot JM, et al. 1141PDAssociation between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. Ann Oncol. 2018;29(suppl_8):mdy288.014-mdy288.014.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"1266_CR67","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1200\/JCO.2018.36.15_suppl.9003","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC. J Clin Oncol. 2018;36(15_suppl):9003.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1266_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","volume":"7","author":"E Verzoni","year":"2019","unstructured":"Verzoni E, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer. 2019;7(1):99.","journal-title":"J Immunother Cancer"},{"issue":"suppl_4","key":"1266_CR69","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBAG Haanen","year":"2017","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2017;28(suppl_4):iv119\u2013iv42.","journal-title":"Ann Oncol"},{"key":"1266_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"F-X Danlos","year":"2018","unstructured":"Danlos F-X, Voisin A-L, Dyevre V, Michot J-M, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21\u20139.","journal-title":"Eur J Cancer"},{"issue":"suppl_8","key":"1266_CR71","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.051","volume":"29","author":"A Gobert","year":"2018","unstructured":"Gobert A, Veyri M, Lavol\u00e9 A, Montaudi\u00e9 H, Cloarec N, Doucet L, et al. 1213P_PRTolerance and efficacy of immune-checkpoint inhibitors for cancer in people living with HIV (PWHIV). Ann Oncol. 2018;29(suppl_8):mdy424.051-mdy424.051.","journal-title":"Ann Oncol"},{"issue":"5","key":"1266_CR72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"1266_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"26","key":"1266_CR74","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"key":"1266_CR75","unstructured":"Results retrieved from ClinicalTrials.gov on 2019-05-03, search: \"other terms\" = \"car t cells\" [internet]. 2019 [cited 2019-05-03]."},{"issue":"9","key":"1266_CR76","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Schussler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397.","journal-title":"EMBO Mol Med"},{"issue":"Suppl 1","key":"1266_CR77","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","volume":"132","author":"SA Grupp","year":"2018","unstructured":"Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, et al. Updated analysis of the efficacy and safety of Tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia. Blood. 2018;132(Suppl 1):895.","journal-title":"Blood."},{"key":"1266_CR78","unstructured":"Borchmann P, Tam CS, J\u00e4ger U, McGuirk JP, Holte H, Waller EK, et al. An updated analysis of JULIET, a global pivotal phase 2 trial of Tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Abstract S799, presented at the annual congress of the European Hematology Association (EHA) 2018."},{"issue":"Suppl 1","key":"1266_CR79","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","volume":"132","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam C, Borchmann P, Jaeger U, Waller EK, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of Tisagenlecleucel. Blood. 2018;132(Suppl 1):1684.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1266_CR80","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2018-99-111368","volume":"132","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. 2-year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of Axicabtagene Ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma. Blood. 2018;132(Suppl 1):2967.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1266_CR81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2018-99-114152","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil LJ, Jain MD, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Axicabtagene Ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience. Blood. 2018;132(Suppl 1):91.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1266_CR82","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood-2018-99-115599","volume":"132","author":"C Summers","year":"2018","unstructured":"Summers C, Annesley C, Bleakley M, Dahlberg A, Jensen MC, Gardner R. Long term follow-up after SCRI-CAR19v1 reveals late recurrences as well as a survival advantage to consolidation with HCT after CAR T cell induced remission. Blood. 2018;132(Suppl 1):967.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1266_CR83","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2018-99-120013","volume":"132","author":"D Sano","year":"2018","unstructured":"Sano D, Nastoupil LJ, Fowler NH, Fayad L, Hagemeister FB, Lee HJ, et al. Safety of Axicabtagene Ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma. Blood. 2018;132(Suppl 1):96.","journal-title":"Blood."},{"issue":"Suppl 1","key":"1266_CR84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood-2018-99-116539","volume":"132","author":"R Faramand","year":"2018","unstructured":"Faramand R, Kotani H, Morrissey D, Yu B, Locke FL, Jain MD, et al. Prediction of CAR T-related toxicities in R\/R DLBCL patients treated with Axicabtagene Ciloleucel using point of care cytokine measurements. Blood. 2018;132(Suppl 1):95.","journal-title":"Blood."},{"key":"1266_CR85","volume-title":"A safe and potent anti-CD19 CAR T cell therapy. Nature medicine","author":"Z Ying","year":"2019","unstructured":"Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, et al. A safe and potent anti-CD19 CAR T cell therapy. Nature medicine. 2019."},{"issue":"2","key":"1266_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2019.01.002","volume":"35","author":"H Du","year":"2019","unstructured":"Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell. 2019;35(2):221\u201337 e8.","journal-title":"Cancer Cell"},{"key":"1266_CR87","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.","journal-title":"Front Pharmacol"},{"key":"1266_CR88","doi-asserted-by":"crossref","unstructured":"Mestermann K, Julian R, Silke F, Hermann E, Hudecek M. Abstract A037: A novel pharmacologic \u201cON\/OFF\u201d switch to modulate CAR-T-cell function in vitro and in vivo. Cancer Immunol Res. 2019;7(2 Supplement):A037-A.","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR18-A037"},{"key":"1266_CR89","doi-asserted-by":"crossref","unstructured":"Geyer MB, Riviere I, Senechal B, Wang X, Wang Y, Purdon TJ, et al. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed\/refractory CLL. JCI Insight. 2019;5.","DOI":"10.1172\/jci.insight.122627"},{"issue":"6","key":"1266_CR90","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):1439\u201353 e19.","journal-title":"Cell."},{"issue":"9","key":"1266_CR91","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847\u201356.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"1266_CR92","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017;21(11):3205\u201319.","journal-title":"Cell Rep"},{"issue":"1","key":"1266_CR93","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257(1):83\u201390.","journal-title":"Immunol Rev"},{"issue":"1","key":"1266_CR94","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000495771","volume":"46","author":"S Kloess","year":"2019","unstructured":"Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U. CAR-expressing natural killer cells for Cancer retargeting. Transfus Med Hemother. 2019;46(1):4\u201313.","journal-title":"Transfus Med Hemother"},{"key":"1266_CR95","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.3389\/fimmu.2018.02166","volume":"9","author":"M Akce","year":"2018","unstructured":"Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The potential of CAR T cell therapy in pancreatic Cancer. Front Immunol. 2018;9:2166.","journal-title":"Front Immunol"},{"issue":"1","key":"1266_CR96","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","volume":"120","author":"N Tokarew","year":"2019","unstructured":"Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26\u201337.","journal-title":"Br J Cancer"},{"issue":"3","key":"1266_CR97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","volume":"131","author":"M Legut","year":"2018","unstructured":"Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood. 2018;131(3):311\u201322.","journal-title":"Blood."},{"key":"1266_CR98","doi-asserted-by":"publisher","first-page":"18851","DOI":"10.1038\/srep18851","volume":"6","author":"MC Raman","year":"2016","unstructured":"Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, et al. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci Rep. 2016;6:18851.","journal-title":"Sci Rep"},{"issue":"6230","key":"1266_CR99","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, NY). 2015;348(6230):62\u20138.","journal-title":"Science (New York, NY)"},{"issue":"4","key":"1266_CR100","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1158\/2326-6066.CIR-18-0888","volume":"7","author":"W Leung","year":"2019","unstructured":"Leung W, Heslop HE. Adoptive immunotherapy with antigen-specific T cells expressing a native TCR. Cancer Immunol Res. 2019;7(4):528\u201333.","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"1266_CR101","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1245\/s10434-007-9788-7","volume":"15","author":"K Dahl","year":"2008","unstructured":"Dahl K, Karlsson M, Marits P, Hoffstedt A, Winqvist O, Th\u00f6rn M. Metinel node\u2014the first lymph node draining a metastasis\u2014contains tumor-reactive lymphocytes. Ann Surg Oncol. 2008;15(5):1454\u201363.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1266_CR102","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1245\/s10434-010-0920-8","volume":"17","author":"M Karlsson","year":"2010","unstructured":"Karlsson M, Marits P, Dahl K, Dag\u00f6\u00f6 T, Enerb\u00e4ck S, Th\u00f6rn M, et al. Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol. 2010;17(7):1747\u201357.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"1266_CR103","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1038\/sj.bjc.6603126","volume":"94","author":"P Marits","year":"2006","unstructured":"Marits P, Karlsson M, Dahl K, Larsson P, Wanders A, Thorn M, et al. Sentinel node lymphocytes: tumour reactive lymphocytes identified intraoperatively for the use in immunotherapy of colon cancer. Br J Cancer. 2006;94(10):1478\u201384.","journal-title":"Br J Cancer"},{"issue":"6184","key":"1266_CR104","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, NY). 2014;344(6184):641\u20135.","journal-title":"Science (New York, NY)"},{"issue":"23","key":"1266_CR105","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in Cancer. N Engl J Med. 2016;375(23):2255\u201362.","journal-title":"N Engl J Med"},{"issue":"6","key":"1266_CR106","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24(6):724\u201330.","journal-title":"Nat Med"},{"key":"1266_CR107","unstructured":"Sarnaik AA TS, Davar D,, editor Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors. 33rd annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018); 2018 November 06."}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1266-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T11:50:26Z","timestamp":1694951426000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1266"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1266-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}